Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial Results

Rhea-AI Summary

Alnylam Pharmaceuticals (Nasdaq: ALNY), a leader in RNAi therapeutics, has announced its plan to report second quarter 2024 financial results on Thursday, August 1, 2024, before U.S. markets open. The company will host a conference call at 8:30 am ET on the same day, where management will provide a company update and discuss Q2 2024 results along with future expectations.

Investors can access a live audio webcast of the call on Alnylam's website in the Investors section. An archived version of the webcast will be available approximately two hours after the event.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2024 on Thursday, August 1, 2024, before the U.S. financial markets open.

Management will provide an update on the Company and discuss second quarter 2024 results as well as expectations for the future via conference call on Thursday, August 1, 2024 at 8:30 am ET. A live audio webcast of the call will be available on the Investors section of the Company’s website at www.alnylam.com/events. An archived webcast will be available on the Alnylam website approximately two hours after the event.

About Alnylam Pharmaceuticals

Alnylam (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding in 2002, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products are ONPATTRO^® (patisiran), AMVUTTRA^® (vutrisiran), GIVLAARI^® (givosiran), OXLUMO^® (lumasiran), and Leqvio^® (inclisiran), which is being developed and commercialized by Alnylam’s partner, Novartis. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its “Alnylam P⁵x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on X (formerly Twitter) at @Alnylam, on LinkedIn, or on Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240718467582/en/

Alnylam Pharmaceuticals, Inc.

Christine Regan Lindenboom

(Investors and Media)

617-682-4340

Josh Brodsky

(Investors)

617-551-8276

Source: Alnylam Pharmaceuticals, Inc.

FAQ

When will Alnylam Pharmaceuticals (ALNY) report its Q2 2024 financial results?

Alnylam Pharmaceuticals (ALNY) will report its second quarter 2024 financial results on Thursday, August 1, 2024, before the U.S. financial markets open.

What time is Alnylam's (ALNY) Q2 2024 earnings conference call scheduled for?

Alnylam's (ALNY) Q2 2024 earnings conference call is scheduled for Thursday, August 1, 2024, at 8:30 am ET.

How can investors access Alnylam's (ALNY) Q2 2024 earnings call?

Investors can access a live audio webcast of Alnylam's (ALNY) Q2 2024 earnings call on the Investors section of the company's website at www.alnylam.com/events.

Will Alnylam (ALNY) provide future guidance during their Q2 2024 earnings call?

While not explicitly stated, Alnylam (ALNY) management will discuss Q2 2024 results and provide expectations for the future during the conference call on August 1, 2024.